Early-Stage Oral Squamous Cell Carcinoma in Adolescents and Young Adults Compared with Older Patients Exhibits Distinct Clinicopathological Features Authors: Sawako Ono, Katsutoshi Hirose, Hotaka Kawai, Tatsuya Abe, Shintaro Sukegawa, Masanori Masui, Chihoko Ikeda, Madoka Isomura, Yuri Tachibana, Junya Ono, Katsumitsu Shimada, Hitoshi Nagatsuka, Hidetaka Yamamoto Published: 2026 ABSTRACT PurposeThis study aimed to compare the clinicopathological features of stage I–II oral squamous cell carcinoma (OSCC) between adolescents and young adults (AYAs) and older patients, and to identify prognostic factors in AYA OSCC.MethodsForty-eight AYA patients aged 15–39 years and 69 older patients aged ≥ 65 years with surgically treated stage I–II OSCC were retrospectively analyzed. Histological evaluation, survival analysis, immunohistochemistry for p53, p16, and MTAP, high-risk HPV RNA in situ hybridization, and fluorescence in situ hybridization for CDKN2A and MTAP were performed.ResultsCompared with older patients, OSCCs in AYAs were more frequently located on the tongue (93.7% vs. 47.8%) and more often exhibited a superficial spreading growth pattern (60.4% vs. 31.8%). AYA tumors more frequently showed modified WPOI-1, high tumor budding, and abnormal p53 immunophenotypes (85.4% vs. 68.1%). AYA patients showed significantly better overall and disease-free survival than older patients. Within the AYA group, depth of invasion (DOI) > 5 mm was associated with distant metastasis and poorer overall and disease-free survival. Postoperative lymph node metastasis occurred in 31.2% of AYAs. Univariable analysis suggested that clinical stage II, tumor thickness > 5 mm, DOI > 5 mm, and tumor budding scores 1–2 were associated with postoperative lymph node metastasis. Molecular status, including p53, p16/CDKN2A, and MTAP, did not provide robust prognostic stratification.ConclusionEarly-stage AYA OSCC exhibits distinct clinicopathological features. DOI was the strongest prognostic indicator, whereas clinical stage, tumor thickness, and tumor budding may provide additional prognostic information regarding the risk of late nodal metastasis.Supplementary InformationThe online version contains supplementary material available at 10.1007/s12105-026-01944-w. Introduction Oral squamous cell carcinoma (OSCC), arising from the oral mucosa, is one of the most common malignant neoplasms in the head and neck region and predominantly affects older adults. Tobacco smoking and alcohol consumption are well-established risk factors, and a subset of cases has also been associated with human papillomavirus (HPV) infection [1, 2]. However, since the 1980s, several countries have reported an increasing incidence of OSCC, particularly oral tongue squamous cell carcinoma, among younger patients, and this trend has persisted in recent decades [3–10]. OSCC in younger patients has attracted increasing attention because many affected individuals lack conventional risk factors such as tobacco smoking and alcohol consumption [8, 9]. Nevertheless, previous studies have used nonuniform definitions of “young” patients, including age cutoffs of ≤ 30, ≤ 40, ≤ 45, or < 50 years, making direct comparisons among studies difficult. In oncology, adolescents and young adults (AYAs) are typically defined as individuals aged 15–39 years, and cancers arising in this age group are increasingly recognized as distinct entities because they often exhibit biological, epidemiological, and clinical characteristics that differ from those observed in pediatric or older adult populations [11–14]. However, studies specifically focusing on OSCC in the AYA population remain limited. Although AYA patients are often reported to present with stage I–II disease, most prognostic analyses of young-onset OSCC have included patients across all disease stages [15–19]. Consequently, prognostic determinants specific to early-stage OSCC in the AYA population remain unclear. Therefore, identifying robust and clinically applicable prognostic factors for early-stage OSCC in AYAs remains an unmet clinical need. At the molecular level, OSCC is characterized by a broad spectrum of genetic alterations, with TP53, CDKN2A, FAT1, NOTCH1, and TERT among the most frequently affected genes [17, 20–22]. Among these, TP53 mutations are among the most common driver events in head and neck squamous cell carcinoma, including OSCC. Aberrant p53 expression patterns on immunohistochemistry (IHC), which can serve as surrogate markers of TP53 alterations, have been associated with adverse clinical outcomes [23–27]. MTAP, which is located adjacent to CDKN2A on chromosome 9p21, is frequently co-deleted with CDKN2A in various malignancies, including oropharyngeal squamous cell carcinoma [28–31]. Accordingly, loss of MTAP expression on IHC has been used as a surrogate marker for CDKN2A/MTAP co-deletion and has also been reported to correlate with clinical outcomes [27, 29–31]. In young patients with OSCC, previous studies have reported TP53 and CDKN2A alterations [17, 32, 33]. However, particularly in early-stage disease, immunohistochemical surrogate biomarkers that reliably predict prognosis in this age group have not been established. Therefore, clinically applicable molecular prognostic markers for early-stage OSCC in AYAs remain to be clarified. Histologically, conventional prognostic factors, including tumor differentiation, tumor thickness, and depth of invasion (DOI), have long been recognized as important predictors of outcome in OSCC [34, 35]. Particularly in early-stage disease, the worst pattern of invasion (WPOI) and tumor budding have been identified as independent prognostic indicators [36, 37]. More recently, modified WPOI criteria and tumor budding-based risk models have been proposed, and their utility for prognostic stratification has been increasingly reported [38, 39]. However, whether these histological risk factors are applicable to early-stage OSCC in AYAs remains insufficiently understood. Therefore, this multicenter retrospective study was designed around two predefined objectives: (1) to characterize the clinicopathological, histopathological, and molecular features of early-stage OSCC in AYAs compared with those in older patients at the same clinical stage; and (2) to identify prognostic factors in AYA OSCC using histological parameters and immunohistochemical surrogate biomarkers that are applicable to routine diagnostic pathology practice. Materials and Methods Patients According to the American Society of Clinical Oncology guidelines, the AYA group was defined as patients aged 15–39 years, whereas the older group was defined as patients aged ≥ 65 years. We retrospectively reviewed the medical records of 48 patients in the AYA group and 69 patients in the older group who underwent surgery for oral squamous cell carcinoma (OSCC) between April 2000 and March 2020 at the participating hospitals. To investigate prognostic factors in early-stage disease, this study was limited to patients with clinical stage I–II OSCC according to the 8th edition of the Union for International Cancer Control/TNM classification [40]. Clinical information, including age at diagnosis, sex, tumor site, smoking and alcohol history, treatment modality, clinical stage, and follow-up status, was collected from the medical records. Particular attention was paid to systemic conditions and cancer predisposition-related backgrounds potentially associated with AYA-onset OSCC, including Fanconi anemia, dyskeratosis congenita, other inherited cancer predisposition syndromes, immunodeficiency, a history of hematopoietic stem cell transplantation, and long-term immunosuppressive therapy. Macroscopic growth patterns were retrospectively classified based on clinical records into three categories: superficial spreading, endophytic, and exophytic types. Superficial spreading lesions were defined as leukoplakia-like lesions with predominant lateral mucosal extension. Endophytic lesions were defined as ulcerative lesions mainly centered in the submucosa, whereas exophytic lesions were defined as outwardly growing mass-forming lesions. The inclusion criteria were the availability of formalin-fixed, paraffin-embedded tumor samples and sufficient clinical data. The study protocol was approved by the Institutional Review Board of Okayama University, Okayama, Japan (No. 2306-037). Histological Evaluation Following Broders’ criteria, OSCCs were classified as well, moderately, or poorly differentiated [41]. The modified WPOI was assessed according to recently proposed criteria that simplify the original five-tier system into three categories [38]. In lesions classified as modified WPOI-1, cancer cell nests are confined within the main tumor boundary, whereas in those classified as modified WPOI-2 or WPOI-3, some nests extend beyond this boundary. The distinction between modified WPOI-2 and WPOI-3 is based on the distance between tumor satellites: < 1 mm for WPOI-2 and ≥ 1 mm for WPOI-3. Scores of 0, 1, and 2 points were assigned to WPOI-1, WPOI-2, and WPOI-3, respectively, when applying the histological risk model described below. The tumor budding score, incorporating tumor budding density and cell dissociation, was defined as follows: 0, no single tumor cells and no tumor buds; 1, low-density tumor budding (< 5 buds); and 2, the presence of single tumor cells and/or high-density tumor budding (≥ 5 buds) per × 200 high-power field [38]. The histopathological risk model proposed by Chang et al. was defined by the total score of modified WPOI (0–2 points) and tumor budding score (0–2 points): low risk (0–1 point), intermediate risk (2–3 points), and high risk (4 points) [38]. In addition, according to the model modified by Almangush et al., cases were reclassified into two groups: low risk (0–2 points) and high risk (3–4 points) [39]. Immunohistochemistry and In Situ Hybridization Serial 4-μm-thick sections cut from FFPE tumor tissues were used for hematoxylin and eosin (H&E) staining and IHC. IHC was performed using the BOND-III automated stainer (Leica Biosystems, Mount Waverley, VIC, Australia), and the following primary antibodies: p53 (Pab1801, 1:2000; Santa Cruz Biotechnology, Dallas, TX, USA), p16 (E6H4, 1:2; Roche, Heidelberg, Germany), and MTAP (42-T, 1:100; Santa Cruz Biotechnology, Dallas, TX, USA). IHC for p53 was evaluated according to the classification system described by Lin et al. [42]. Tumor specimens were categorized into wild-type (p53-conventional), wild-type (p53-HPV), and abnormal expression patterns. The wild-type pattern comprised four subtypes: (1) scattered basal (p53-conventional), defined as scattered p53-positive cells involving < 25% of the basal and/or parabasal layer; (2) patchy basal/parabasal (p53-conventional), characterized by variable weak to focally strong nuclear expression in 25–75% of the basal and/or parabasal layer; (3) mid-epithelial/basal sparing (p53-HPV), characterized by strong mid-epithelial staining with absent or markedly reduced staining in the basal layer; and (4) markedly reduced (null-like)/basal sparing (p53-HPV), characterized by basal sparing with significantly attenuated staining in > 70% of the mid-epithelial layer. The abnormal pattern also included four subtypes: (1) overexpression, basal/parabasal and diffuse, defined as strong and uniform nuclear staining in > 75% of atypical basal and parabasal cells with extension into more than three epithelial layers; (2) overexpression, basal/parabasal only, defined as strong and uniform nuclear p53 staining in > 75% of atypical basal and parabasal cells; (3) null pattern, defined as complete absence of p53 nuclear and cytoplasmic staining, with positive staining observed only in lymphocytes serving as internal controls; and (4) cytoplasmic pattern, defined as weak, moderate, or strong cytoplasmic staining in tumor cells, with or without nuclear staining, for which the presence of both positive and negative internal controls was required. Positive p16 protein expression (i.e., overexpression) was defined as ≥ 70% of tumor cells showing strong and diffuse nuclear and cytoplasmic staining [43]. For p16-positive cases, in situ hybridization (ISH) was performed to detect HPV RNA using an E6/E7 mRNA probe set (Advanced Cell Diagnostics, Newark, CA, USA) targeting 18 high-risk HPV types (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82) with the RNAscope 2.5 HD reagent kit (Advanced Cell Diagnostics), according to the manufacturer’s protocol. Any nuclear or cytoplasmic dot signal was considered positive [44]. Retention of MTAP expression was defined as cytoplasmic expression in tumor cells regardless of nuclear staining. Loss of MTAP expression was defined as the absence of cytoplasmic expression in tumor cells in the presence of positive internal controls, such as inflammatory cells or endothelial cells, as previously described [35]. Fluorescence In Situ Hybridization for CDKN2A and MTAP Deletion Fluorescence in situ hybridization (FISH) was performed in cases with MTAP loss. FISH was carried out on 4-μm-thick FFPE tissue sections using the p16/CEN9q Dual Color FISH Probe (Product No. GC002, GSP Lab, Kanagawa, Japan) to evaluate CDKN2A copy number and the MTAP/CEN9q Dual Color FISH Probe (Product No. GC206, GSP Lab) to assess MTAP copy number. Hybridization was performed at 37 °C for 24 h following 10 min of denaturation at 75 °C in a hybridizer (Dako, Glostrup, Denmark). Slides were examined using a BZ-X700 fluorescence microscope (Keyence, Osaka, Japan). Green and red signals corresponded to FITC-labeled CEN9q and Texas Red-labeled p16 or MTAP, respectively. FISH signals were evaluated in at least 50 tumor cell nuclei. Cases were defined as having homozygous deletion of CDKN2A when green (CEN9q)-only signal patterns, indicating loss of both red (p16) signals, were observed in > 30% of cells. If this criterion was not met, but loss of one red (p16) signal was observed in > 30% of cells, the case was defined as having hemizygous deletion of CDKN2A. The same criteria were applied for the evaluation of MTAP deletion [35]. Statistical Analysis Categorical variables were analyzed using the chi-squared test or Fisher’s exact test, as appropriate, and continuous variables were compared using the t-test. Percentages were rounded and may not total 100% because of rounding. Overall survival (OS) was defined as the time from diagnosis to death from any cause. Disease-free survival (DFS) was defined as the time from diagnosis to the first documented disease progression or relapse. Disease-specific survival (DSS) was defined as the time from diagnosis to death caused by OSCC. Patients who died from causes unrelated to cancer were censored at the time of death for DFS and DSS analyses. The follow-up period was calculated from the date of initial treatment to the date of last clinical follow-up or death. Survival curves were estimated using the Kaplan–Meier method and compared using the log-rank test. In the AYA group, logistic regression analyses were performed to assess the associations of clinicopathological variables with late lymph node metastasis and distant metastasis. Univariable and multivariable models were used to estimate odds ratios with 95% confidence intervals. Statistical significance was set at p ≤ 0.05. All analyses were performed using R software (version 4.5.1). Results Clinical Findings The clinical findings of the AYA and older patients with OSCC are summarized in Table 1. The AYA group predominantly comprised patients in their 30 s (75.0%), whereas the older group mainly consisted of patients in their 70 s (60.9%). No significant difference in sex distribution was observed between the two groups (p = 0.34). A history of smoking was significantly less frequent in the AYA group than in the older group (33.3% vs 63.8%, p < 0.01). In contrast, no significant difference was observed in the history of alcohol consumption between the two groups (39.5% vs 55.1%, p = 0.20). Among the AYA patients, one had a history of hematopoietic stem cell transplantation for acute myeloid leukemia, and another had systemic lupus erythematosus with antiphospholipid syndrome. No other AYA patients had a documented history of systemic disease, immunodeficiency, autoimmune disease, or known inherited cancer predisposition syndromes, including Fanconi anemia and dyskeratosis congenita.Table 1Clinical findings of OSCC in AYA and older patientsFactorsAYA (n = 48)Older (n = 69)PAge group (%)10 s3 (6.3)0 (0)20 s9 (18.7)0 (0)30 s36 (75.0)0 (0)60 s0 (0)14 (20.3)70 s0 (0)42 (60.9)80 s0 (0)13 (18.8)Sex (%)Male27 (56.2)45 (65.2)0.34Female21 (43.8)24 (34.8)Smoking history (%)< 0.01Yes16 (33.3)44 (63.8)No23 (47.9)19 (27.5)Unknown9 (18.8)6 (8.7)Alcohol drinking history (%)0.20Yes19 (39.5)38 (55.1)No18 (37.5)21 (30.4)Unknown11 (22.9)10 (14.5)Tumor site (%)< 0.01Tongue45 (93.7)33 (47.8)Floor of the mouth3 (6.3)7 (10.2)Buccal mucosa0 (0)17 (24.6)Gingiva0 (0)12 (17.4)Macroscopic growth pattern (%) < 0.01Superficial spreading type29 (60.4)22 (31.8)Exophytic type10 (20.8)25 (36.2)Endophytic type7 (14.6)22 (31.8)Unclassifiable2 (4.2)0 (0)Clinical stage/TNM 8th (%)0.08Stage I / T1N0M033 (68.7)36 (52.2)Stage II / T2N0M015 (31.3)33 (47.8)Treatment (%)< 0.01Surgery only47 (97.9)16 (23.2)Surgery + ND1 (2.1)52 (75.4)Subtotal maxillectomy + ND0 (0)1 (1.4)Postoperative local recurrence (%)0.29Yes5 (10.4)13 (18.8)No43 (89.6)56 (81.2)Postoperative lymph node metastasis (%)0.19Yes15 (31.2)14 (20.3)No33 (68.8)55 (79.7)Postoperative distant metastasis (%)0.48Yes5 (10.4)4 (5.8)No43 (89.6)65 (94.2)Survival status (%)0.01Alive without OSCC43 (89.6)50 (72.5)Alive with OSCC1 (2.1)2 (2.9)Dead from OSCC4 (8.3)7 (10.1)Dead from other disease0 (0)10 (14.5)Values are presented as n (%). Categorical variables were compared using the chi-squared test or Fisher’s exact test, as appropriate. Bold values indicate statistical significance (p < 0.05)AYA adolescents and young adults, OSCC oral squamous cell carcinoma, TNM tumor-node-metastasis, ND neck dissection Table 1Clinical findings of OSCC in AYA and older patientsFactorsAYA (n = 48)Older (n = 69)PAge group (%)10 s3 (6.3)0 (0)20 s9 (18.7)0 (0)30 s36 (75.0)0 (0)60 s0 (0)14 (20.3)70 s0 (0)42 (60.9)80 s0 (0)13 (18.8)Sex (%)Male27 (56.2)45 (65.2)0.34Female21 (43.8)24 (34.8)Smoking history (%)< 0.01Yes16 (33.3)44 (63.8)No23 (47.9)19 (27.5)Unknown9 (18.8)6 (8.7)Alcohol drinking history (%)0.20Yes19 (39.5)38 (55.1)No18 (37.5)21 (30.4)Unknown11 (22.9)10 (14.5)Tumor site (%)< 0.01Tongue45 (93.7)33 (47.8)Floor of the mouth3 (6.3)7 (10.2)Buccal mucosa0 (0)17 (24.6)Gingiva0 (0)12 (17.4)Macroscopic growth pattern (%) < 0.01Superficial spreading type29 (60.4)22 (31.8)Exophytic type10 (20.8)25 (36.2)Endophytic type7 (14.6)22 (31.8)Unclassifiable2 (4.2)0 (0)Clinical stage/TNM 8th (%)0.08Stage I / T1N0M033 (68.7)36 (52.2)Stage II / T2N0M015 (31.3)33 (47.8)Treatment (%)< 0.01Surgery only47 (97.9)16 (23.2)Surgery + ND1 (2.1)52 (75.4)Subtotal maxillectomy + ND0 (0)1 (1.4)Postoperative local recurrence (%)0.29Yes5 (10.4)13 (18.8)No43 (89.6)56 (81.2)Postoperative lymph node metastasis (%)0.19Yes15 (31.2)14 (20.3)No33 (68.8)55 (79.7)Postoperative distant metastasis (%)0.48Yes5 (10.4)4 (5.8)No43 (89.6)65 (94.2)Survival status (%)0.01Alive without OSCC43 (89.6)50 (72.5)Alive with OSCC1 (2.1)2 (2.9)Dead from OSCC4 (8.3)7 (10.1)Dead from other disease0 (0)10 (14.5)Values are presented as n (%). Categorical variables were compared using the chi-squared test or Fisher’s exact test, as appropriate. Bold values indicate statistical significance (p < 0.05)AYA adolescents and young adults, OSCC oral squamous cell carcinoma, TNM tumor-node-metastasis, ND neck dissection Clinical findings of OSCC in AYA and older patients Values are presented as n (%). Categorical variables were compared using the chi-squared test or Fisher’s exact test, as appropriate. Bold values indicate statistical significance (p < 0.05) AYA adolescents and young adults, OSCC oral squamous cell carcinoma, TNM tumor-node-metastasis, ND neck dissection Tumor site distribution differed significantly between the two groups (p < 0.01), with tongue tumors being more common in the AYA group (93.7% vs 47.8%), whereas buccal mucosal and gingival tumors were observed only in the older group. Macroscopic growth patterns also differed significantly between the groups (p < 0.01), with superficial spreading lesions predominating in AYA patients and exophytic and endophytic lesions being more frequent in older patients. No multiple lesions were observed in AYA patients. T1 or stage I disease (8th UICC/TNM classification) tended to be more frequent in the AYA group than in the older group (68.7% vs 52.2%), although this difference was not significant (p = 0.08). Treatment modalities differed significantly between the groups (p < 0.01), with the vast majority (97.9%) of with the vast majority (97.9%) of AYA patients undergoing surgery alone without neck dissection, and most (75.4%) older patients receiving surgery with neck dissection. Rates of postoperative local recurrence, delayed lymph node metastasis, and distant metastasis did not differ significantly between the groups; however, the rate of delayed postoperative lymph node metastasis tended to be higher in the AYA group than in the older group (31.2% vs 20.3%). At the point of final follow-up, survival status differed significantly between the groups (p = 0.01): the AYA group had a higher proportion of patients alive without OSCC (89.6% vs 72.5%) and no deaths from other diseases (0% vs 14.5%) than the older group. Histopathological Findings Representative histopathological images are shown in Fig. 1. The proportions of each pathological factor in the AYA and older groups are presented in Fig. 2. A summary of the histopathological parameters is provided in Table 2. There were no significant differences in tumor thickness, DOI, or tumor differentiation between the two groups (Fig. 2A). The distribution of modified WPOI differed significantly between the two groups (p = 0.03); the older group was more frequently scored as WPOI-2 than the AYA group (Fig. 2B). No case of WPOI-3 was identified in either group. Tumor budding scores also differed significantly between the two groups (p = 0.02); AYA patients exhibited tumor budding score 2 (41.7%) more often than older patients (18.9%), whereas AYA patients less frequently showed tumor budding score 0 than older patients (35.4% vs 56.5%) (Fig. 2C). According to the histopathological risk model of Chang et al. [38], no significant difference was observed between the AYA and older groups (p = 0.45), and no case was classified as high risk in either group (Fig. 2D). In contrast, according to the histopathological risk model of Almangush et al. [39], AYA patients were more frequently classified as high risk (3–4 points) than older patients (39.6% vs 18.8%, p = 0.02) (Fig. 2E). No significant differences were observed in lymphovascular invasion or perineural invasion between the AYA and older groups.Fig. 1Representative histopathological images of tumor differentiation, modified worst pattern of invasion (WPOI), and tumor budding in oral squamous cell carcinoma. A Well-differentiated squamous cell carcinoma showing large tumor nests with prominent keratinization and squamous differentiation. B Moderately to poorly differentiated squamous cell carcinoma showing reduced squamous differentiation and increased cytological atypia. C Modified WPOI-1, with tumor nests confined within the main tumor boundary. D Modified WPOI-2, characterized by tumor nests extending beyond the tumor border (arrow). E Tumor budding score 0, with no identifiable tumor budding. F Tumor budding score 1, with tumor budding composed of tumor clusters containing fewer than 5 tumor cells (arrow). G Tumor budding score 2, with frequent tumor budding and occasional isolated single tumor cells at the invasive front (arrows)Fig. 2Comparison of histopathological parameters between AYA and older patients with oral squamous cell carcinoma. A Tumor differentiation. The distribution of well-differentiated and moderately to poorly differentiated tumors is similar between the two groups. B Modified WPOI. Modified WPOI-2 is more frequent in older patients, whereas modified WPOI-1 is more common in AYA patients. C Tumor budding score. AYA patients are more often scored as budding score 2, whereas older patients more frequently exhibit a budding score of 0. D Histopathological risk model by Chang et al. AYA and older patient groups show similar distributions of low (0–1 point) or intermediate (2–3 points) cases. E Histopathological risk model by Almangush et al. High-risk tumors (3–4 points) are more frequent in the AYA group, whereas low-risk tumors (0–2 points) are more common in the older group. The proportions of each category are shown as 100% stacked bar charts. Categorical variables were compared using the chi-squared test or Fisher’s exact test, as appropriate. AYA, adolescents and young adults; WPOI, worst pattern of invasionTable 2Histopathological findings of OSCC in AYA and older patientsFactorsAYA (n = 48)Older (n = 69)PTumor thickness (%)0.409≤ 5 mm28 (58.3)45 (65.2)> 5 mm20 (41.7)24 (34.8)Depth of invasion (%)0.97≤ 5 mm35 (72.9)53 (76.8)> 5 mm13 (27.1)16 (23.2)Tumor differentiation (%)0.70Well31 (64.6)42 (60.9)Moderate–poor17 (35.4)27 (39.1)Modified WPOI (%)0.031 (0 point)22 (45.8)18 (26.1)2 (1 point)26 (54.2)51 (73.9)3 (2 points)0 (0)0 (0)Tumor budding score (%)0.020 point17 (35.4)39 (56.5)1 point11 (22.9)17 (24.6)2 points20 (41.7)13 (18.9)Histopathological risk model by Chang (%)0.45Low (0–1 point)23 (47.9)39 (56.5)Intermediate (2–3 points)25 (52.1)30 (43.5)High (4 points)0 (0)0 (0)Histopathological risk model by Almangush (%)0.02Low (0–2 points)29 (60.4)56 (81.2)High (3–4 points)19 (39.6)13 (18.8)Lymphovascular invasion (%)0.79Absent40 (83.3)59 (85.5)Present8 (16.7)10 (14.5)Perineural invasion (%)0.12Absent41 (85.4)65 (94.2)Present7 (14.6)4 (5.8)Values are presented as n (%). Categorical variables were compared using the chi-squared test or Fisher’s exact test, as appropriate. Bold values indicate statistical significance (p < 0.05)AYA adolescents and young adults, OSCC oral squamous cell carcinoma, WPOI worst pattern of invasion Representative histopathological images of tumor differentiation, modified worst pattern of invasion (WPOI), and tumor budding in oral squamous cell carcinoma. A Well-differentiated squamous cell carcinoma showing large tumor nests with prominent keratinization and squamous differentiation. B Moderately to poorly differentiated squamous cell carcinoma showing reduced squamous differentiation and increased cytological atypia. C Modified WPOI-1, with tumor nests confined within the main tumor boundary. D Modified WPOI-2, characterized by tumor nests extending beyond the tumor border (arrow). E Tumor budding score 0, with no identifiable tumor budding. F Tumor budding score 1, with tumor budding composed of tumor clusters containing fewer than 5 tumor cells (arrow). G Tumor budding score 2, with frequent tumor budding and occasional isolated single tumor cells at the invasive front (arrows) Comparison of histopathological parameters between AYA and older patients with oral squamous cell carcinoma. A Tumor differentiation. The distribution of well-differentiated and moderately to poorly differentiated tumors is similar between the two groups. B Modified WPOI. Modified WPOI-2 is more frequent in older patients, whereas modified WPOI-1 is more common in AYA patients. C Tumor budding score. AYA patients are more often scored as budding score 2, whereas older patients more frequently exhibit a budding score of 0. D Histopathological risk model by Chang et al. AYA and older patient groups show similar distributions of low (0–1 point) or intermediate (2–3 points) cases. E Histopathological risk model by Almangush et al. High-risk tumors (3–4 points) are more frequent in the AYA group, whereas low-risk tumors (0–2 points) are more common in the older group. The proportions of each category are shown as 100% stacked bar charts. Categorical variables were compared using the chi-squared test or Fisher’s exact test, as appropriate. AYA, adolescents and young adults; WPOI, worst pattern of invasion Table 2Histopathological findings of OSCC in AYA and older patientsFactorsAYA (n = 48)Older (n = 69)PTumor thickness (%)0.409≤ 5 mm28 (58.3)45 (65.2)> 5 mm20 (41.7)24 (34.8)Depth of invasion (%)0.97≤ 5 mm35 (72.9)53 (76.8)> 5 mm13 (27.1)16 (23.2)Tumor differentiation (%)0.70Well31 (64.6)42 (60.9)Moderate–poor17 (35.4)27 (39.1)Modified WPOI (%)0.031 (0 point)22 (45.8)18 (26.1)2 (1 point)26 (54.2)51 (73.9)3 (2 points)0 (0)0 (0)Tumor budding score (%)0.020 point17 (35.4)39 (56.5)1 point11 (22.9)17 (24.6)2 points20 (41.7)13 (18.9)Histopathological risk model by Chang (%)0.45Low (0–1 point)23 (47.9)39 (56.5)Intermediate (2–3 points)25 (52.1)30 (43.5)High (4 points)0 (0)0 (0)Histopathological risk model by Almangush (%)0.02Low (0–2 points)29 (60.4)56 (81.2)High (3–4 points)19 (39.6)13 (18.8)Lymphovascular invasion (%)0.79Absent40 (83.3)59 (85.5)Present8 (16.7)10 (14.5)Perineural invasion (%)0.12Absent41 (85.4)65 (94.2)Present7 (14.6)4 (5.8)Values are presented as n (%). Categorical variables were compared using the chi-squared test or Fisher’s exact test, as appropriate. Bold values indicate statistical significance (p < 0.05)AYA adolescents and young adults, OSCC oral squamous cell carcinoma, WPOI worst pattern of invasion Histopathological findings of OSCC in AYA and older patients Values are presented as n (%). Categorical variables were compared using the chi-squared test or Fisher’s exact test, as appropriate. Bold values indicate statistical significance (p < 0.05) AYA adolescents and young adults, OSCC oral squamous cell carcinoma, WPOI worst pattern of invasion Immunoexpression Patterns of p53 Immunohistochemical findings are summarized in Table 3. Three patterns of abnormal p53 expression were observed: (1) overexpression, basal/parabasal and diffuse; (2) overexpression, basal/parabasal only; and (3) null pattern (Fig. 3A, left). No cytoplasmic p53 staining pattern was observed in either group. Wild-type p53 expression was either scattered basal or patchy basal/parabasal pattern, whereas no p53-HPV pattern (i.e., mid-epithelial/basal sparing or markedly reduced [null-like]/basal sparing) was observed in either group (Fig. 3A, right). Abnormal expression of p53 was significantly more frequent in AYA patients (41/48, 85.4%) than in older patients (47/69, 68.1%) (p = 0.03, Fig. 3B). Wild-type p53 expression was seen in 7/48 (14.6%) AYA cases and 22/69 (31.9%) older cases.Table 3Immunohistochemical and molecular findings of OSCC in AYA and older patientsFactorsAYA (n = 48)Older (n = 69)Pp53-IHC0.03Abnormal pattern (%)41 (85.4)47 (68.1)Wild type pattern (%)7 (14.6)22 (31.9)p16-IHC0.43Positive (%)4 (8.3)3 (4.3)Negative (%)44 (91.7)66 (95.7)MTAP-IHC1.00Retained (%)44 (91.7)63 (91.3)Loss (%)4 (8.3)6 (8.7)CDKN2A-FISH0.40Intact (%)1 (25.0)0 (0)Homozygous deletion (%)3 (75.0)6 (100)MTAP-FISH0.40Intact (%)1 (25.0)0 (0)Homozygous deletion (%)3 (75.0)6 (100)Values are presented as n (%). Categorical variables were compared using the chi-squared test or Fisher’s exact test, as appropriate. CDKN2A and MTAP FISH analyses were performed only in p16-negative and MTAP-loss cases. Bold value indicates statistical significance (p < 0.05)AYA adolescents and young adults, OSCC oral squamous cell carcinoma, IHC immunohistochemistry, MTAP methylthioadenosine phosphorylase, FISH fluorescence in situ hybridizationFig. 3Representative p53 immunohistochemical patterns and their distribution in AYA versus older OSCC patients. A Representative p53 immunohistochemical staining patterns. Abnormal (mutant-type) patterns include basal/parabasal and diffuse nuclear overexpression (abnormal subtype 1), basal/parabasal-only overexpression (abnormal subtype 2), and null pattern (abnormal subtype 3). Wild-type patterns include scattered basal staining (wild subtype 1) and patchy basal/parabasal staining (wild subtype 2). B The prevalence of abnormal or wild-type expression in each age group. Abnormal expression of p53 is significantly more frequent in AYA patients (41/48, 85.4%) than in older patients (47/69, 68.1%) (p = 0.03). C The proportion of abnormal subtypes of p53 expression in each group. Within the AYA group, subtypes 1, 2, and 3 show similar proportions (31.7%, 34.1%, and 34.1%, respectively). Within the older group, subtype 1 is the most frequent (46.8%), followed by subtype 2 (31.9%) and subtype 3 (21.3%). D The proportion of subtypes of wild-type p53 expression in each age group. In both groups, most cases are subtype 1 (71.4% and 68.2%), and the remaining cases are subtype 2 (28.6% and 31.8%). The proportions of each category are shown as 100% stacked bar charts. Categorical variables were compared using the chi-squared test or Fisher’s exact test, as appropriate. AYA, adolescents and young adults Table 3Immunohistochemical and molecular findings of OSCC in AYA and older patientsFactorsAYA (n = 48)Older (n = 69)Pp53-IHC0.03Abnormal pattern (%)41 (85.4)47 (68.1)Wild type pattern (%)7 (14.6)22 (31.9)p16-IHC0.43Positive (%)4 (8.3)3 (4.3)Negative (%)44 (91.7)66 (95.7)MTAP-IHC1.00Retained (%)44 (91.7)63 (91.3)Loss (%)4 (8.3)6 (8.7)CDKN2A-FISH0.40Intact (%)1 (25.0)0 (0)Homozygous deletion (%)3 (75.0)6 (100)MTAP-FISH0.40Intact (%)1 (25.0)0 (0)Homozygous deletion (%)3 (75.0)6 (100)Values are presented as n (%). Categorical variables were compared using the chi-squared test or Fisher’s exact test, as appropriate. CDKN2A and MTAP FISH analyses were performed only in p16-negative and MTAP-loss cases. Bold value indicates statistical significance (p < 0.05)AYA adolescents and young adults, OSCC oral squamous cell carcinoma, IHC immunohistochemistry, MTAP methylthioadenosine phosphorylase, FISH fluorescence in situ hybridization Immunohistochemical and molecular findings of OSCC in AYA and older patients Values are presented as n (%). Categorical variables were compared using the chi-squared test or Fisher’s exact test, as appropriate. CDKN2A and MTAP FISH analyses were performed only in p16-negative and MTAP-loss cases. Bold value indicates statistical significance (p < 0.05) AYA adolescents and young adults, OSCC oral squamous cell carcinoma, IHC immunohistochemistry, MTAP methylthioadenosine phosphorylase, FISH fluorescence in situ hybridization Representative p53 immunohistochemical patterns and their distribution in AYA versus older OSCC patients. A Representative p53 immunohistochemical staining patterns. Abnormal (mutant-type) patterns include basal/parabasal and diffuse nuclear overexpression (abnormal subtype 1), basal/parabasal-only overexpression (abnormal subtype 2), and null pattern (abnormal subtype 3). Wild-type patterns include scattered basal staining (wild subtype 1) and patchy basal/parabasal staining (wild subtype 2). B The prevalence of abnormal or wild-type expression in each age group. Abnormal expression of p53 is significantly more frequent in AYA patients (41/48, 85.4%) than in older patients (47/69, 68.1%) (p = 0.03). C The proportion of abnormal subtypes of p53 expression in each group. Within the AYA group, subtypes 1, 2, and 3 show similar proportions (31.7%, 34.1%, and 34.1%, respectively). Within the older group, subtype 1 is the most frequent (46.8%), followed by subtype 2 (31.9%) and subtype 3 (21.3%). D The proportion of subtypes of wild-type p53 expression in each age group. In both groups, most cases are subtype 1 (71.4% and 68.2%), and the remaining cases are subtype 2 (28.6% and 31.8%). The proportions of each category are shown as 100% stacked bar charts. Categorical variables were compared using the chi-squared test or Fisher’s exact test, as appropriate. AYA, adolescents and young adults The proportion of subtypes of abnormal p53 expression in each age group is shown in Fig. 3C. Within the AYA group (n = 41), the three subtypes showed nearly equal distribution: basal/parabasal and diffuse overexpression (abnormal subtype 1; 13 cases, 31.7%), basal/parabasal only overexpression (abnormal subtype 2; 14 cases, 34.1%), and null pattern (abnormal subtype 3; 14 cases, 34.1%). Within the older group (n = 47), subtype 1 was the most frequent (22 cases, 46.8%), followed by subtype 2 (15 cases, 31.9%) and subtype 3 (10 cases, 21.3%). The proportion of wild-type p53 expression subtypes was similar between the AYA and older groups (Fig. 3D): scattered basal staining (wild subtype 1; 5/7 [71.4%] vs 15/22 [68.2%]) and patchy basal/parabasal staining (wild subtype 2; 2/7 [28.6%] vs 7/22 [31.8%]). p16 and MTAP Status and HPV Infection Overexpression of p16 was seen in 4/48 (8.3%) AYA cases and 3/69 (4.3%) older cases (p = 0.43) (Table 3). All p16-positive cases were tested for high-risk HPV RNA ISH, but none of them was positive for HPV. Loss of expression of MTAP was seen in 4/48 (8.3%) AYA cases and 6/69 (8.7%) older cases (p = 1.00). A total of 10 cases (4 AYA and 6 older) with loss of MTAP expression were also negative for p16 expression (Fig. 4A, B). FISH analyses for CDKN2A and MTAP were performed in these p16-negative/MTAP-loss cases. In the AYA group, 3/4 cases (75%) showed homozygous deletions of both CDKN2A and MTAP genes by FISH, consistent with the IHC pattern (Fig. 4A–D), whereas the remaining one (25%) showed intact biallelic signals of both CDKN2A and MTAP genes despite the negative expression of p16 and MTAP on IHC (Fig. 4E–H). In contrast, all older cases (n = 6) showed homozygous deletion of both CDKN2A and MTAP by FISH.Fig. 4Immunohistochemical and FISH status of p16/CDKN2A and MTAP in AYA OSCC patients. A–D A representative case with negative expression of p16 and MTAP and homozygous deletion of CDKN2A and MTAP genes. Immunohistochemically, tumor cells lack p16 expression (A). Tumor cells show complete loss of MTAP expression, with preserved staining in internal control cells (B). FISH shows homozygous deletions of CDKN2A (C) and MTAP (D). Red signals indicating CDKN2A or MTAP are totally absent, whereas two green signals indicating CEN9q are preserved in each tumor cell. E–H An exceptional case of negative expression of p16 and MTAP and intact CDKN2A and MTAP genes. Immunohistochemically, tumor cells are negative for p16 (E) and MTAP (F). FISH for CDKN2A (G) and MTAP (H) shows intact signals, as shown by paired green signals (CEN9q) and red signals (CDKN2A or MTAP) Immunohistochemical and FISH status of p16/CDKN2A and MTAP in AYA OSCC patients. A–D A representative case with negative expression of p16 and MTAP and homozygous deletion of CDKN2A and MTAP genes. Immunohistochemically, tumor cells lack p16 expression (A). Tumor cells show complete loss of MTAP expression, with preserved staining in internal control cells (B). FISH shows homozygous deletions of CDKN2A (C) and MTAP (D). Red signals indicating CDKN2A or MTAP are totally absent, whereas two green signals indicating CEN9q are preserved in each tumor cell. E–H An exceptional case of negative expression of p16 and MTAP and intact CDKN2A and MTAP genes. Immunohistochemically, tumor cells are negative for p16 (E) and MTAP (F). FISH for CDKN2A (G) and MTAP (H) shows intact signals, as shown by paired green signals (CEN9q) and red signals (CDKN2A or MTAP) Prognostic Analyses Kaplan–Meier analysis demonstrated significantly better overall survival (OS) and disease-free survival (DFS) in the AYA group than in the older group (OS, p = 0.024; DFS, p = 0.044) (Fig. 5). In contrast, disease-specific survival (DSS) was not significantly different between the AYA and older groups (p = 0.68).Fig. 5Kaplan–Meier survival curves comparing AYA and older patients with OSCC. A Overall survival (OS) by age group (AYA vs older). B Disease-free survival (DFS) by age group (AYA vs older). C Disease-specific survival (DSS) by age group (AYA vs older). The AYA group is shown in red and the comparator group in teal. The AYA group shows significantly better OS and DFS than the older group (p = 0.024 and p = 0.044, respectively), whereas DSS is not significantly different between the AYA and older groups (p = 0.68). Tick marks indicate censored observations. The x-axis indicates follow-up time (months), and the y-axis indicates survival probability Kaplan–Meier survival curves comparing AYA and older patients with OSCC. A Overall survival (OS) by age group (AYA vs older). B Disease-free survival (DFS) by age group (AYA vs older). C Disease-specific survival (DSS) by age group (AYA vs older). The AYA group is shown in red and the comparator group in teal. The AYA group shows significantly better OS and DFS than the older group (p = 0.024 and p = 0.044, respectively), whereas DSS is not significantly different between the AYA and older groups (p = 0.68). Tick marks indicate censored observations. The x-axis indicates follow-up time (months), and the y-axis indicates survival probability To identify prognostic factors in the AYA group, Kaplan–Meier analyses were performed for multiple pathological parameters, including tumor thickness, DOI, tumor differentiation, histopathological risk, p53 expression pattern, and MTAP status. Tumor thickness (≤ 5 mm vs. > 5 mm) was not associated with prognostic differences (OS: p = 0.16; DFS: p = 0.098) (Fig. 6A,B). Cases with DOI > 5 mm showed significantly worse OS and DFS than those with DOI ≤ 5 mm (OS: log-rank p = 0.032; DFS: log-rank p = 0.012) (Fig. 6C, D). In contrast, tumor differentiation, histopathological risk category, p53 expression pattern, and MTAP status were not associated with prognostic differences within the AYA group (Supplementary Fig. 1).Fig. 6Kaplan–Meier survival analyses according to tumor thickness and depth of invasion (DOI) in AYA OSCC patients. A Overall survival (OS) stratified by tumor thickness (≤ 5 mm vs > 5 mm). B Disease-free survival (DFS) stratified by tumor thickness (≤ 5 mm vs > 5 mm). C OS stratified by DOI (≤ 5 mm vs > 5 mm). D DFS stratified by DOI (≤ 5 mm vs > 5 mm). Tumor thickness is not associated with the difference in OS (A: p = 0.16) and DFS (B: p = 0.098). DOI > 5 mm is significantly associated with shorter OS (C: p = 0.032) and DFS (D: p = 0.012) Kaplan–Meier survival analyses according to tumor thickness and depth of invasion (DOI) in AYA OSCC patients. A Overall survival (OS) stratified by tumor thickness (≤ 5 mm vs > 5 mm). B Disease-free survival (DFS) stratified by tumor thickness (≤ 5 mm vs > 5 mm). C OS stratified by DOI (≤ 5 mm vs > 5 mm). D DFS stratified by DOI (≤ 5 mm vs > 5 mm). Tumor thickness is not associated with the difference in OS (A: p = 0.16) and DFS (B: p = 0.098). DOI > 5 mm is significantly associated with shorter OS (C: p = 0.032) and DFS (D: p = 0.012) Logistic regression analyses were subsequently performed to clarify the risk factors for postoperative lymph node metastasis, as well as distant metastasis, in the AYA group (Table 4). Regarding postoperative lymph node metastasis, stage II disease, tumor thickness > 5 mm, DOI > 5 mm, and tumor budding (scores 1–2) were significantly associated with the outcome on univariable analysis. However, none of these variables was significant after multivariable adjustment, although tumor budding showed a strong trend toward association. Despite the small number of distant metastatic events resulting in wide confidence intervals and limited precision, DOI > 5 mm was significantly associated with distant metastasis on both univariable and multivariable analyses.Table 4Logistic regression analysis of clinicopathological factors associated with late lymph node metastasis and distant metastasis in AYA OSCCVariablePostoperative lymph node metastasisPostoperative distant metastasisUnivariable OR (95% CI)PMultivariable adjusted OR (95% CI)PUnivariable OR (95% CI)PMultivariable adjusted OR (95% CI)PClinical stage II (vs stage I)6.75 (1.73–26.30)0.0063.12 (0.45–21.54)0.2491.54 (0.23–10.33)0.6570.63 (0.07–5.55)0.681Tumor thickness > 5 mm (vs ≤ 5 mm)4.60 (1.25–16.97)0.0223.58 (0.72–17.85)0.1192.37 (0.24–23.10)0.4581.24 (0.05–30.86)0.896Depth of invasion > 5 mm (vs ≤ 5 mm)3.94 (1.02–15.13)0.0462.19 (0.27–17.55)0.46015.11 (1.50–152.42)0.02115.11 (1.50–152.42)0.021Tumor differentiation, moderate–poor (vs well)2.01 (0.57–7.07)0.2761.21 (0.24–6.15)0.8149.23 (0.94–90.78)0.0574.07 (0.34–49.15)0.270Modified WPOI score 1 point (vs 0 points)3.30 (0.87–12.53)0.0795.05 (0.58–43.97)0.1421.30 (0.20–8.61)0.7830.74 (0.09–6.22)0.780Tumor budding score 1–2 points (vs 0 points)5.42 (1.05–27.89)0.0434.94 (0.82–29.61)0.0812.37 (0.24–23.10)0.4582.26 (0.20–25.77)0.512Chang’s histopathological risk model, intermediate (vs low)2.40 (0.67–8.58)0.1780.69 (0.04–12.45)0.8021.43 (0.22–9.44)0.7090.76 (0.09–6.47)0.804Almangush’s histopathological risk model, high (vs low)1.03 (0.29–3.57)0.968NANA1.02 (0.15–6.75)0.9840.79 (0.10–6.27)0.820p53 abnormal (vs wild-type)3.11 (0.34–28.45)0.3151.70 (0.12–24.98)0.700NANANANAMTAP loss (vs retained)0.71 (0.07–7.49)0.7793.73 (0.22–62.39)0.360NANANANAOdds ratios were estimated using logistic regression analyses. NA indicates that the odds ratio could not be estimated because of an insufficient number of events. Bold values indicate statistical significance (p < 0.05)AYA adolescents and young adults, OSCC oral squamous cell carcinoma, OR odds ratio, CI confidence interval, WPOI worst pattern of invasion, MTAP methylthioadenosine phosphorylase, NA not available Table 4Logistic regression analysis of clinicopathological factors associated with late lymph node metastasis and distant metastasis in AYA OSCCVariablePostoperative lymph node metastasisPostoperative distant metastasisUnivariable OR (95% CI)PMultivariable adjusted OR (95% CI)PUnivariable OR (95% CI)PMultivariable adjusted OR (95% CI)PClinical stage II (vs stage I)6.75 (1.73–26.30)0.0063.12 (0.45–21.54)0.2491.54 (0.23–10.33)0.6570.63 (0.07–5.55)0.681Tumor thickness > 5 mm (vs ≤ 5 mm)4.60 (1.25–16.97)0.0223.58 (0.72–17.85)0.1192.37 (0.24–23.10)0.4581.24 (0.05–30.86)0.896Depth of invasion > 5 mm (vs ≤ 5 mm)3.94 (1.02–15.13)0.0462.19 (0.27–17.55)0.46015.11 (1.50–152.42)0.02115.11 (1.50–152.42)0.021Tumor differentiation, moderate–poor (vs well)2.01 (0.57–7.07)0.2761.21 (0.24–6.15)0.8149.23 (0.94–90.78)0.0574.07 (0.34–49.15)0.270Modified WPOI score 1 point (vs 0 points)3.30 (0.87–12.53)0.0795.05 (0.58–43.97)0.1421.30 (0.20–8.61)0.7830.74 (0.09–6.22)0.780Tumor budding score 1–2 points (vs 0 points)5.42 (1.05–27.89)0.0434.94 (0.82–29.61)0.0812.37 (0.24–23.10)0.4582.26 (0.20–25.77)0.512Chang’s histopathological risk model, intermediate (vs low)2.40 (0.67–8.58)0.1780.69 (0.04–12.45)0.8021.43 (0.22–9.44)0.7090.76 (0.09–6.47)0.804Almangush’s histopathological risk model, high (vs low)1.03 (0.29–3.57)0.968NANA1.02 (0.15–6.75)0.9840.79 (0.10–6.27)0.820p53 abnormal (vs wild-type)3.11 (0.34–28.45)0.3151.70 (0.12–24.98)0.700NANANANAMTAP loss (vs retained)0.71 (0.07–7.49)0.7793.73 (0.22–62.39)0.360NANANANAOdds ratios were estimated using logistic regression analyses. NA indicates that the odds ratio could not be estimated because of an insufficient number of events. Bold values indicate statistical significance (p < 0.05)AYA adolescents and young adults, OSCC oral squamous cell carcinoma, OR odds ratio, CI confidence interval, WPOI worst pattern of invasion, MTAP methylthioadenosine phosphorylase, NA not available Logistic regression analysis of clinicopathological factors associated with late lymph node metastasis and distant metastasis in AYA OSCC Odds ratios were estimated using logistic regression analyses. NA indicates that the odds ratio could not be estimated because of an insufficient number of events. Bold values indicate statistical significance (p < 0.05) AYA adolescents and young adults, OSCC oral squamous cell carcinoma, OR odds ratio, CI confidence interval, WPOI worst pattern of invasion, MTAP methylthioadenosine phosphorylase, NA not available Discussion With respect to the first objective, the stage-matched comparison revealed a distinct clinicopathological profile of AYA OSCC. Clinically, AYA tumors were predominantly located on the tongue and more frequently exhibited a superficial spreading growth pattern, which was defined in this study as leukoplakia-like lesions with predominant lateral mucosal extension. This clinical presentation is noteworthy because such lesions may not be immediately suspected to represent invasive carcinoma, particularly in young patients. Therefore, increased awareness of this superficial spreading pattern among dentists and clinicians may facilitate earlier recognition and appropriate biopsy of OSCC in the AYA population. Leukoplakia-like mucosal changes may also occur in the context of field cancerization, which is characterized by genetically altered mucosa surrounding or distant from the primary tumor [42, 43]. Molecular field changes in OSCC have been associated with TP53 mutations and loss at 9p21, including the CDKN2A locus [44, 45]. In the present study, abnormal p53 expression was significantly more frequent in AYA tumors than in older tumors, suggesting the possible involvement of TP53-related alterations. In contrast, MTAP loss and homozygous deletions of CDKN2A and MTAP were infrequent. Although none of the AYA patients had multiple lesions and clinically evident field cancerization was therefore not strongly supported, the presence of subclinical molecular field changes cannot be excluded, because adjacent non-neoplastic mucosa was not subjected to molecular analysis. Changes in sexual behavior have been suggested to increase oral HPV infection and contribute to early-onset head and neck cancers [46]. However, high-risk HPV was not detected in any AYA tumors in the present study. Although some AYA patients had been exposed to conventional risk factors, such as tobacco smoking and alcohol consumption, patients without such exposures were also observed. In addition, most AYA patients had no documented history of known inherited cancer predisposition syndromes. OSCC has been reported in young female patients without conventional cancer-related risk factors, suggesting the existence of a distinct subgroup of young patients who develop OSCC in the absence of established etiological factors [47]. Taken together, these findings suggest that mechanisms other than HPV infection and conventional environmental exposures may contribute to OSCC development in a subset of AYA patients. Further studies are needed to clarify the possible involvement of unrecognized genetic susceptibility or as-yet unidentified etiological factors. Regarding the second objective, the most important finding of the present study was that DOI emerged as the most robust prognostic indicator in early-stage AYA OSCC. Recent studies have suggested that DOI and tumor thickness may have comparable predictive performance, raising the possibility that tumor thickness could serve as a surrogate for DOI, because histological assessment of tumor thickness is usually easier than that of DOI [48]. In contrast, tumor thickness was not significantly associated with prognosis in the present AYA group. Similarly, other pathological parameters, including modified WPOI, tumor budding score, histopathological risk models, and p53 and MTAP expression patterns, did not show clear prognostic associations. OSCC in young patients has been reported to show more aggressive histopathological features, including higher tumor budding [49]. Consistent with this, AYA tumors in the present study showed higher tumor budding scores and were more frequently classified into the high-risk category according to the Almangush risk model than tumors in older patients. Although the high-risk group in this model has been reported to be significantly associated with poor survival [39], the AYA group in the present study showed significantly better OS and DFS than the older group. These findings suggest that conventional histopathological risk models may not fully capture prognosis in early-stage AYA OSCC. Taken together, DOI may provide prognostic information beyond tumor thickness and other histopathological factors in AYA patients with early-stage OSCC and should therefore be prioritized as a histopathological indicator for risk assessment. Lymph node status is one of the independent prognostic factors in OSCC, and younger patients have been reported to have a higher prevalence of regional metastasis, which may contribute to poorer prognosis [50, 51]. In the present study, univariable analysis showed that clinical stage II, tumor thickness > 5 mm, DOI > 5 mm, and tumor budding scores of 1–2 were associated with late lymph node metastasis in the AYA group. These findings suggest that AYA patients with these risk factors may require closer postoperative surveillance and individualized consideration of additional neck treatment or adjuvant therapy. This study has several limitations. First, because the number of adverse events, including distant metastasis, was limited in the AYA group, robust multivariable analysis could not be performed, and the results of the univariable analyses should therefore be interpreted with caution. Second, molecular analyses were limited to immunohistochemistry, HPV RNA in situ hybridization, and selected FISH assays; comprehensive genomic profiling was not performed. In conclusion, early-stage OSCCs in AYAs exhibited distinct clinicopathological and molecular surrogate phenotypes compared with those in older patients. DOI emerged as the most robust prognostic indicator in the AYA group, suggesting that DOI-prioritized, AYA-specific prognostic models may be useful for clinical management. Although most AYA patients in the present study were treated with surgery alone, our findings suggest that postoperative management, including adjuvant treatment to reduce the risk of late lymph node recurrence, may be warranted in selected patients. Clinicopathological risk factors, including clinical stage, tumor thickness, DOI, and tumor budding score, may help guide such decision-making. Supplementary Information Below is the link to the electronic supplementary material.Supplementary Material 1. Fig. 1 Kaplan–Meier analyses of OS and DFS by histological and molecular factors in AYA OSCC. (A-1, A-2) OS and DFS stratified by tumor differentiation (Well vs Moderate–poor). (B-1, B-2) OS and DFS stratified by histological risk model by Chang (Intermediate vs Low). (C-1, C-2) OS and DFS stratified by histological risk model by Almangush (High vs Low). (D-1, D-2) OS and DFS stratified by p53 immunophenotype (Abnormal vs Wild). (E-1, E-2) OS and DFS stratified by MTAP status (Lost vs Retained). Tick marks indicate censored observations. P values were calculated using the log-rank test. No significant differences are observed across comparisons (A-1, p = 0.078; A-2, p = 0.11; B-1, p = 0.92; B-2, p = 0.98; C-1, p = 0.57; C-2, p = 0.53; D-1, p = 0.37; D-2, p = 0.40; E-1, p = 0.62; E-2, p = 0.52). Supplementary Material 1. Fig. 1 Kaplan–Meier analyses of OS and DFS by histological and molecular factors in AYA OSCC. (A-1, A-2) OS and DFS stratified by tumor differentiation (Well vs Moderate–poor). (B-1, B-2) OS and DFS stratified by histological risk model by Chang (Intermediate vs Low). (C-1, C-2) OS and DFS stratified by histological risk model by Almangush (High vs Low). (D-1, D-2) OS and DFS stratified by p53 immunophenotype (Abnormal vs Wild). (E-1, E-2) OS and DFS stratified by MTAP status (Lost vs Retained). Tick marks indicate censored observations. P values were calculated using the log-rank test. No significant differences are observed across comparisons (A-1, p = 0.078; A-2, p = 0.11; B-1, p = 0.92; B-2, p = 0.98; C-1, p = 0.57; C-2, p = 0.53; D-1, p = 0.37; D-2, p = 0.40; E-1, p = 0.62; E-2, p = 0.52).